NOTE 4 - SUBSEQUENT EVENTS In October 2017, th
Post# of 15624
In October 2017, the Company initiated a Phase I safety study at Sheba,blind, randomized, placebo controlled, multiple escalating dose study to determine the safety, tolerability and pharmacokinetic profile of medical grade cannabis in healthy volunteers.